Delhi High Court Restrains Scott Edil From Selling 'Nexporin', 'Zetum' Over Similarity With GSK Marks
On 5 Aug, Delhi High Court Justice Jyoti Singh granted GSK an ex-parte ad-interim injunction restraining Scott Edil Pharmacia and affiliate from selling or advertising “Nexporin” and “Zetum”. The court found the marks deceptively similar to GSK’s registered “Neosporin” and “Ceftum” and ordered removal of related listings within two weeks.
How this was made
The 30-second read
Why it matters
The court found prima facie deceptive similarity between “Nexporin” vs “Neosporin” and “Zetum” vs “Ceftum,” restraining manufacturing, selling, advertising, and requiring takedown of listings within two weeks until the next hearing.
Market read
For traders, this is a legal enforcement catalyst that can affect near-term product availability and marketing for the specific marks in India, but the article provides no financial scale.
What to watch
The article does not quantify sales exposure, duration of the injunction beyond the interim period, or whether Scott Edil has viable alternative marks or appeal strategy.
Background
GSK sought an ex-parte ad-interim injunction in Delhi High Court against Scott Edil Pharmacia and an affiliate over allegedly deceptively similar pharmaceutical trademarks.
Ticker impact
GSK is the applicant seeking an ex-parte ad-interim injunction over Scott Edil’s “Nexporin” and “Zetum” marks, alleging trademark infringement.
Limited direct impact on GSK’s traded fundamentals, but it reduces near-term competitive brand risk in the specific product category.
The order is jurisdictional and brand-focused, with no disclosed financial magnitude; any market impact is likely marginal for GSK’s overall earnings.
Market effects
Highlights heightened enforcement risk for branded generic or similar-named pharma products in India, potentially affecting other trademark-adjacent launches.
India-focused injunction could constrain a local competitor’s marketing and listings for the restrained marks.
Mostly local legal risk; limited spillover to global pharma pricing unless similar disputes broaden.
Counterpoint
Even with an injunction, the restrained company may pivot to alternative branding or formulations, limiting long-run competitive damage.
Key entities
- plaintiff/applicantGlaxoSmithKline Pharmaceuticals Limited
Sought and obtained an interim injunction restraining Scott Edil’s use of similar trademark marks in India.
- defendantScott Edil Pharmacia Limited
Restrained from manufacturing, selling, advertising, and listing products under “Nexporin” and “Zetum” (and similar marks) pending further proceedings.
- courtDelhi High Court
Granted the interim restraint and set the matter for further proceedings with the injunction application returnable on 3 December 2026.
